Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis

Proton pump inhibitors (PPI) are an invaluable therapy option for acid related diseases; however, PPI therapy is also linked to a series of side effects in cirrhosis, such as microbiome alterations, spontaneous bacterial peritonitis and hepatic encephalopathy. Decision tools to balance benefits and...

Descripción completa

Detalles Bibliográficos
Autores principales: Horvath, Angela, Rainer, Florian, Bashir, Mina, Leber, Bettina, Schmerboeck, Bianca, Klymiuk, Ingeborg, Groselj-Strele, Andrea, Durdevic, Marija, Freedberg, Daniel E., Abrams, Julian A., Fickert, Peter, Stiegler, Philipp, Stadlbauer, Vanessa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700098/
https://www.ncbi.nlm.nih.gov/pubmed/31427714
http://dx.doi.org/10.1038/s41598-019-48352-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700098/
https://www.ncbi.nlm.nih.gov/pubmed/31427714
http://dx.doi.org/10.1038/s41598-019-48352-5

Ejemplares similares